Skip to content
Peptigraph home

Tesamorelin vs Ipamorelin: What the Research Shows

Tesamorelin and Ipamorelin side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[15]Growth hormoneGHRP (ghrelin receptor agonist)Not FDA approved · research chemicalIpamorelinGhrelin-receptor agonist peptide, not FDA-approved; in a randomized trial after bowel resection, median time to first tolerated meal was 25.3 versus 32.6 hours with placebo.[12]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Tesamorelin if…

  • you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[5]
  • you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[15]

Consider Ipamorelin if…

  • you want the option with a randomized human trial, though it found no significant difference from placebo (postoperative ileus): median time to first tolerated meal was 25.3 h vs 32.6 h[12]

What they have in common

  • WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[2]
  • WADA prohibits growth hormone secretagogues at all times; its list names ibutamoren (MK-677) and ipamorelin[2]
Ipamorelin is not FDA approved. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 8 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldTesamorelinIpamorelin
ClassGHRH analogGHRP (ghrelin receptor agonist)
Also calledtesa, Egriftaipa, ipam
FDA statusFDA approved (Egrifta)Not FDA approved · research chemical
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A direct-urine screen includes ipamorelin among the peptides it can detect, at 50 to 500 pg/mL.PMID 26578461
Half-life11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658
Human studies we summarised12 human (11 randomized or controlled) of 16 summarised2 human (2 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg, 20 mg2 mg, 5 mg, 10 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Sold mixed: Tesamorelin + Ipamorelin

These blends put both in one vial. The blend calculator works out the dose of each component per draw. Evidence for the combination: No studies tested these together (PubMed search: 6 results, 2 Oct 2026).

Blend calculator

A releasing-hormone analogue versus a ghrelin-pathway peptide

Tesamorelin has phase 3 data on abdominal fat in HIV and on liver fat; ipamorelin has no trial on fat of any kind in people.[7]

Ipamorelin's only patient trial tested recovery of gut function after bowel surgery; the median time to a tolerated meal was not significantly shorter than on placebo.[12]

In rats, ipamorelin increased body weight and bone measures, but these are animal results with no counterpart in human fat or muscle.[16]

Tesamorelin's human data even include muscle: a secondary analysis found area and density improved in those whose visceral fat fell.[8]

Both raise GH, but tesamorelin's effect on IGF-I was measured over months and was large, while ipamorelin's GH peak was a single brief pulse.[11]

Safety notes, label status and sport

Tesamorelin is the only one with a US label, for HIV-associated abdominal fat, and it states it is not for weight loss.[5]

FDA's review of compounded ipamorelin cites death in a study of intravenous use for gut motility, a signal absent from the tesamorelin label.[17]

Tesamorelin's label warns of fluid retention that may include swelling, joint pain and carpal tunnel syndrome.[5]

The two share a prohibited-list section, tesamorelin as a GHRH analogue and ipamorelin as a secretagogue.[2]

Ipamorelin has a measured half-life of a couple of hours in healthy men, while tesamorelin's label gives it in minutes.[11]

Common questions

Is tesamorelin better than ipamorelin?

Tesamorelin has randomised trials and an approved label; ipamorelin's only patient trial missed its efficacy endpoints.[12]

Which is better for belly fat, tesamorelin or ipamorelin?

Only tesamorelin has human evidence on abdominal fat, in HIV-associated lipodystrophy, with a label that excludes general weight loss.[15]

Can you take tesamorelin and ipamorelin together?

No study tests the pair, and both appear on the prohibited list.[2]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  4. 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  5. 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  7. 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  8. 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  9. 9Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  10. 10Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
  11. 11Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  12. 12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  13. 13The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
  14. 14PubMed search: (ipamorelin[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  16. 16The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
  17. 17Official web pageOfficial web page · web page

Found an error? Report a correction.